Q-omics provides the consensus-scored NEU4 profile across patient tissues and cancer cell-line models. NEU4 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NEU4 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, NEU4 RNA expression shows 14,554 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, COAD, and TGCT as cancer lineages where NEU4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NEU4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NEU4 survival associations across molecular data types. NEU4 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NEU4 RNA expression–survival associations across cancer types. High NEU4 expression shows unfavorable associations in ACC, KIRP, LUAD and UCEC, but favorable associations in LGG and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NEU4 RNA expression.
This table summarizes NEU4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NEU4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NEU4 shows lower tumor expression in COAD, KICH, KIRP, KIRC, CHOL and LIHC. The COAD box plot shows higher NEU4 RNA expression in normal versus tumor tissue (log2 FC = −2.124, t-test p < 0.001).
This table shows molecular features associated with NEU4 in patient tissues and cancer cell lines. In patient samples, NEU4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NEU4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
